Skip to main content
ENDO 2026 Main banner

General Endocrinology

PL03-02 - Mechanism-Based Discovery of a New Generation of Endocrine Therapies for Breast and Prostate Cancer

Sunday, June 14, 2026
8:45 AM - 9:15 AM CT
Location: Main Stage (Room W375DE)
Disclosure(s):
Donald McDonnell, PhD: Adara Pharmaceuticals: Owner/Co-Owner Founder/Co-Founder (); Bristol Myers Squibb: Consultant (), Grant Recipient (); Coregen: Advisory Board (); Daichi Sankyo: Consultant (); Foghorn Therapeutics: Consultant (); Interdict Bio: Advisory Board (); Menarini: Grant Recipient (), Intellectual property (); Pappas Capital: Advisory Board (); Parabilis Medicine: Consultant (); Precede Therapeutics: Consultant (), Grant Recipient (); Rappta Pharmaceuticals: Advisory Board (); Stemline: Consultant ()